AR123045A1 - Forma cristalina de clorhidrato de fentermina y proceso de obtención de la misma - Google Patents
Forma cristalina de clorhidrato de fentermina y proceso de obtención de la mismaInfo
- Publication number
- AR123045A1 AR123045A1 ARP210102065A ARP210102065A AR123045A1 AR 123045 A1 AR123045 A1 AR 123045A1 AR P210102065 A ARP210102065 A AR P210102065A AR P210102065 A ARP210102065 A AR P210102065A AR 123045 A1 AR123045 A1 AR 123045A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline form
- phentermine hydrochloride
- obtaining
- phentermine
- hydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
- C07C209/86—Separation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a la forma cristalina de clorhidrato de fentermina monohidratada y a procesos de obtención de dicha forma cristalina. Fentermina o 2-metil-1-fenilpropan-2-amina se encuentra en forma de sal de clorhidrato, siendo un estimulante del sistema nervioso central, utilizado como un supresor del apetito y estimulante en medicamentos. Reivindicación 1: Forma cristalina de clorhidrato de fentermina caracterizada por ser la forma monohidratada. Reivindicación 2: Forma cristalina, de acuerdo con la reivindicación 1, caracterizada por comprender picos expresados en grados 2-q (±0,2º) a 13,3; 13,7; 14,3; 14,7; 15,1; 16,0; 18,4; 19,5; 20,5; 21,2; 22,2, 22,7; 23,3; 24,4; 24,8; 25,8; 26,4; 27,4; 28,2; 28,6; 29,1; 29,8; 30,5; 31,6; 32,3; 32,9; 34,2; 34,9; 36,0; 36,6; 37,3; 38,2; 39,5; 40,0; 40,4; 43,1; 43,6; 45,1; 46,1; 47,1; 47,6; 48,9; 52,9 y 54,2 en su difractograma de rayos X. Reivindicación 5: Proceso de obtención de la forma cristalina de clorhidrato de fentermina, tal como se define en cualquiera de las reivindicaciones 1 a 4, caracterizado por comprender las etapas de: (a) granulación de alto cizallamiento de clorhidrato de fentermina en forma anhidra; (b) adición de solución granulante a la mezcla del granulado de (a); (c) mezcla del granulado de (a) y de la solución granulante de (b) obteniendo un polvo; y (d) secado del polvo en un lecho fluidizado o en un horno o en un horno de vacío. Reivindicación 8: Proceso de obtención de la forma cristalina de clorhidrato de fentermina, tal como se define en una cualquiera de las reivindicaciones 1 a 4, caracterizado por comprender las etapas de: (a) recristalización de la suspensión o solución de la forma anhidra de clorhidrato de fentermina en agua o en una mezcla de agua con solventes volátiles; y, (b) secado en horno u horno de vacío o filtración al vacío de la solución. Reivindicación 12: Proceso de obtención de la forma cristalina de clorhidrato de fentermina, tal como se define en una cualquiera de las reivindicaciones de 1 a 4, caracterizado por comprender las etapas de: (a) exposición de la forma anhidra de clorhidrato de fentermina a atmósfera con alta condición de humedad en una cámara de humedad controlada; y, (b) secado en horno u horno de vacío o filtración al vacío de la solución.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/BR2020/050290 WO2022020910A1 (pt) | 2020-07-27 | 2020-07-27 | Forma cristalina de cloridrato de fentermina e processo de obtenção da mesma |
Publications (1)
Publication Number | Publication Date |
---|---|
AR123045A1 true AR123045A1 (es) | 2022-10-26 |
Family
ID=79283588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210102065A AR123045A1 (es) | 2020-07-27 | 2021-07-23 | Forma cristalina de clorhidrato de fentermina y proceso de obtención de la misma |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230265043A1 (es) |
EP (1) | EP4190320A4 (es) |
AR (1) | AR123045A1 (es) |
BR (1) | BR112023001519A2 (es) |
CA (1) | CA3187100A1 (es) |
CO (1) | CO2023000499A2 (es) |
MX (1) | MX2023001136A (es) |
PE (1) | PE20231051A1 (es) |
UY (1) | UY39335A (es) |
WO (1) | WO2022020910A1 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2408345A (en) | 1942-04-13 | 1946-09-24 | Wm S Merrell Co | Composition of matter and method |
US20080293695A1 (en) | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
CA2617688C (en) * | 2007-02-22 | 2015-08-18 | Alpex Pharma S.A. | Solid dosage formulations containing weight-loss drugs |
WO2009098169A1 (en) * | 2008-02-05 | 2009-08-13 | Alpex Pharma Sa | Orally disintegrating tablets with speckled appearance |
AR074199A1 (es) * | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer. |
IN2012DE00826A (es) * | 2012-03-21 | 2015-08-21 | Ranbaxy Lab Ltd | |
CN103316026B (zh) * | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
-
2020
- 2020-07-27 CA CA3187100A patent/CA3187100A1/en active Pending
- 2020-07-27 EP EP20947537.5A patent/EP4190320A4/en active Pending
- 2020-07-27 PE PE2023000061A patent/PE20231051A1/es unknown
- 2020-07-27 US US18/006,430 patent/US20230265043A1/en active Pending
- 2020-07-27 BR BR112023001519A patent/BR112023001519A2/pt unknown
- 2020-07-27 WO PCT/BR2020/050290 patent/WO2022020910A1/pt active Application Filing
- 2020-07-27 MX MX2023001136A patent/MX2023001136A/es unknown
-
2021
- 2021-07-22 UY UY0001039335A patent/UY39335A/es unknown
- 2021-07-23 AR ARP210102065A patent/AR123045A1/es unknown
-
2023
- 2023-01-17 CO CONC2023/0000499A patent/CO2023000499A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3187100A1 (en) | 2022-02-03 |
EP4190320A4 (en) | 2024-05-01 |
BR112023001519A2 (pt) | 2023-02-14 |
PE20231051A1 (es) | 2023-07-11 |
MX2023001136A (es) | 2023-03-21 |
EP4190320A1 (en) | 2023-06-07 |
US20230265043A1 (en) | 2023-08-24 |
CO2023000499A2 (es) | 2023-03-17 |
WO2022020910A1 (pt) | 2022-02-03 |
UY39335A (es) | 2021-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016343633B2 (en) | Valbenazine salts and polymorphs thereof | |
US8642606B2 (en) | ZAP-70 active compounds | |
AU2010250099B2 (en) | Solid pharmaceutical compositions and processes for their production | |
CN101031572A (zh) | (r/s)利福霉素衍生物,它们的制备和药物组合物 | |
JP2004534047A5 (es) | ||
ES2702194T3 (es) | Compuestos de 6,7-dihidropirazolo[1,5-]pirazin-4(5H)-ona y su uso como moduladores alostéricos negativos de receptores mGlu2 | |
MXPA04000905A (es) | Derivados de amino-ftalazinona activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
KR20160032021A (ko) | 야누스 키나제(jak) 억제제의 바이설페이트 및 그의 제조 방법 | |
JP2021105043A (ja) | 非溶媒和物結晶及びその製造方法、並びに応用 | |
TWI666020B (zh) | 固體分散製劑 | |
AR123045A1 (es) | Forma cristalina de clorhidrato de fentermina y proceso de obtención de la misma | |
AU2009318027A1 (en) | Process for recovering florfenicol from pharmaceutical compositions | |
AU2007262750A1 (en) | Novel hydrate form of moxifloxacin monohydrochloride | |
KR20210089210A (ko) | 실질적 비정질인 메조포러스 탄산마그네슘을 포함하는 신규한 비정질 활성 제약 성분 | |
KR102233199B1 (ko) | 항균성 화합물 | |
US20100331376A1 (en) | Process for Recovering Flunixin From Pharmaceutical Compositions | |
JPH01199977A (ja) | セファロスポリン誘導体の結晶、その製造法およびそれらを有効成分とする医薬組成物 | |
US6767556B2 (en) | Pharmaceutical compositions comprising moexipril magnesium | |
AU2022359222A1 (en) | A new class of antiviral drugs | |
CA3221427A1 (en) | Novel manufacturing method of daprodustat and precursors thereof | |
JP2005519070A (ja) | 7−(((5−アミノ−1,2,4−チアジアゾール−3−イル)(フルオロメトキシイミノ)アセチル)アミノ)−3−((イミノ−1−ピペラジニルメチル)メチルヒドラゾノ)−メチル−3−セフェム−4−カルボン酸の結晶質塩酸塩 | |
SI23610A (sl) | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji | |
JP2010285356A (ja) | β−ラクタム化合物の安定形結晶の製造方法 | |
HRP20100345T1 (hr) | Kristalne forme makrolidnih spojeva koji ispoljavaju anti-inflamatornu aktivnost | |
LT3870B (en) | Diastereomers of 3-cefem-4-carboxylic acid 1-(isopropoxy-carbonyloxy)ethyl ester, process for preparingthereof, antibacteric preparations based on same and process for preparation thereof |